Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 13:15:1.
doi: 10.1186/2050-6511-15-1.

Hypersensitivity to oxaliplatin: clinical features and risk factors

Marie Parel, Florence Ranchon, Audrey Nosbaum, Benoit You, Nicolas Vantard, Vérane Schwiertz, Chloé Gourc, Noémie Gauthier, Marie-Gabrielle Guedat, Sophie He, Eléna Kiouris, Céline Alloux, Thierry Vial, Véronique Trillet-Lenoir, Gilles Freyer, Frédéric Berard, Catherine Rioufol  1
Affiliations

Hypersensitivity to oxaliplatin: clinical features and risk factors

Marie Parel et al. BMC Pharmacol Toxicol. .

Abstract

Background: Oxaliplatin-based regimens induce a potential risk of hypersensitivity reaction (HSR), with incidence varying from 10% to 25% and lack of clearly identified risk factors. The present study aimed to assess incidence and risk factors in HSR.

Methods: All patients treated with oxaliplatin in the Medical Oncology Department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) from October 2004 to January 2011 were enrolled. Incidence and severity of HSR were analyzed retrospectively and the potential clinicopathological covariates were tested on univariate and multivariate analysis.

Results: A total of 1,221 doses of oxaliplatin were administered for 191 patients, 8.9% of whom experienced an HSR. Seventeen HSRs were observed, with 1.6% grade 3 and no grade 4 events. The first reaction appeared after a median of 3 oxaliplatin infusions. Using univariate analysis, HSR was associated with younger age (mean age, 56.2 years; p = 0.04), female gender (p = 0.01) and prior exposure to platinum salts (p = 0.02). No increased risk was associated with mean dose or with presence of atopic background. Multivariate analysis confirmed that women were at higher risk of oxaliplatin HSR than men (p < 0.05). Reintroduction of oxaliplatin was effective in 64.7% of hypersensitive patients using an appropriate premedication strategy. Patients who experienced a grade 3 HSR were not rechallenged.

Conclusion: The risk of developing oxaliplatin HSR should not be underestimated (8.9% of patients). The medical team's vigilance should be increased with women, younger patients and patients with prior exposure to platinum salts.

PubMed Disclaimer

References

    1. Joerger M. Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol. 2012;23(10):x313–319. - PubMed
    1. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:1–11. - PMC - PubMed
    1. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc. 2010;109(5):362–368. doi: 10.1016/S0929-6646(10)60064-2. - DOI - PubMed
    1. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004;5(10):2159–2170. doi: 10.1517/14656566.5.10.2159. - DOI - PubMed
    1. Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Levy E, Hardy-Bessard AC, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H. et al.Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer. 2009;100(4):601–607. doi: 10.1038/sj.bjc.6604878. - DOI - PMC - PubMed